Inhalable PEGylated phospholipid nanocarriers and PEGylated therapeutics for respiratory delivery as aerosolized colloidal dispersions and dry powder inhalers

Pharmaceutics

Volumn 6, Issue 2, 2014, Pages 333-353

  Muralidharan, Priya ^a   Mallory, Evan ^a   Malapit, Monica ^a   Don Jr , Hayes ^b,c   Mansour, Heidi M ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Aerosol; Lung; Nasal; PEGylated inhalation powders; PEGylated liposomes; PEGylated micelles; Solid state PEGylated bilayer nanocarriers; Sterically stabilized nanoparticles

Indexed keywords

BUDESONIDE; CALCITONIN; CIPROFLOXACIN; CONNECTIVE TISSUE GROWTH FACTOR; CURCUMIN; GLUCAGON LIKE PEPTIDE 1; GROWTH FACTOR; INSULIN; LIPOSOME; LOW MOLECULAR WEIGHT HEPARIN; LYSINE; MACROGOL; NANOCARRIER; PACLITAXEL; PEGYLATED PHOSPHOLIPID NANOCARRIER; PHOSPHOLIPID; SMALL INTERFERING CONNECTIVE TISSUE GROWTH FACTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS DNA;

AEROSOL; ALZHEIMER DISEASE; ASTHMA; BLOOD BRAIN BARRIER; BONE DISEASE; CENTRAL NERVOUS SYSTEM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG RELEASE; DRUG TARGETING; DRY POWDER INHALER; GENE TARGETING; HUMAN; KIDNEY CLEARANCE; LUNG CANCER; LUNG EMBOLISM; LUNG FIBROSIS; MOLECULAR WEIGHT; MONONUCLEAR PHAGOCYTE; NANOMEDICINE; NEBULIZER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOPOROSIS; RESPIRATORY TRACT INFECTION; REVIEW; UPPER RESPIRATORY TRACT;

EID: 84902961070     PISSN: None     EISSN: 19994923     Source Type: Journal    
DOI: 10.3390/pharmaceutics6020333     Document Type: Review

References (87)

1. Hickey, A.J.; Mansour, H.M. Chapter 5: Delivery of drugs by the pulmonary route. In Modern Pharmaceutics: Applications and Advances, 5th ed.; Taylor & Francis, Inc.: New York, NY, USA, 2009; pp. 191-219.
2. Pison, U.; Welte, T.; Giersig, M.; Groneberg, D.A. Nanomedicine for respiratory diseases. Eur. J. Pharmacol. 2006, 533, 341-350.
3. Mansour, H.M.; Rhee, Y.S.; Wu, X. Nanomedicine in pulmonary delivery. Int. J. Nanomed. 2009, 4, 299-319.
4. Sahib, M.N.; Darwis, Y.; Peh, K.K.; Abdulameer, S.A.; Tan, Y.T. Rehydrated sterically stabilized phospholipid nanomicelles of budesonide for nebulization: Physicochemical characterization and in vitro, in vivo evaluations. Int. J. Nanomed. 2011, 6, 2351-2366.
5. Ryan, G.M.; Kaminskas, L.M.; Kelly, B.D.; Owen, D.J.; McIntosh, M.P.; Porter, C.J. Pulmonary administration of pegylated polylysine dendrimers: Absorption from the lung versus retention within the lung is highly size-dependent. Mol. Pharm. 2013, 10, 2986-2995.
6. Knop, K.; Hoogenboom, R.; Fischer, D.; Schubert, U.S. Poly(ethylene glycol) in drug delivery: Pros and cons as well as potential alternatives. Angew. Chem. Int. Ed. Engl. 2010, 49, 6288-6308.
7. Veronese, F.M.; Pasut, G. Pegylation, successful approach to drug delivery. Drug Discov. Today 2005, 10, 1451-1458.
8. Karathanasis, E.; Ayyagari, A.L.; Bhavane, R.; Bellamkonda, R.V.; Annapragada, A.V. Preparation of in vivo cleavable agglomerated liposomes suitable for modulated pulmonary drug delivery. J. Control. Release 2005, 103, 159-175.
9. Harris, J.M.; Chess, R.B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2003, 2, 214-221.
10. Sakagami, M. Systemic delivery of biotherapeutics through the lung: Opportunities and challenges for improved lung absorption. Ther. Deliv. 2013, 4, 1511-1525.
11. Vonarbourg, A.; Passirani, C.; Saulnier, P.; Simard, P.; Leroux, J.C.; Benoit, J.P. Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake. J. Biomed. Mater. Res. A 2006, 78, 620-628.
12. Nag, O.K.; Awasthi, V. Surface engineering of liposomes for stealth behavior. Pharmaceutics 2013, 5, 542-569.
13. Fee, C.J. Size comparison between proteins pegylated with branched and linear poly(ethylene glycol) molecules. Biotechnol. Bioeng. 2007, 98, 725-731.
14. Youn, Y.S.; Kwon, M.J.; Na, D.H.; Chae, S.Y.; Lee, S.; Lee, K.C. Improved intrapulmonary delivery of site-specific pegylated salmon calcitonin: Optimization by peg size selection. J. Control. Release 2008, 125, 68-75.
15. Gursahani, H.; Riggs-Sauthier, J.; Pfeiffer, J.; Lechuga-Ballesteros, D.; Fishburn, C.S. Absorption of polyethylene glycol (peg) polymers: The effect of peg size on permeability. J. Pharm. Sci. 2009, 98, 2847-2856.
16. Mansour, H.M.; Park, C.-W.; Hayes, D. Jr. Nanoparticle lung delivery and inhalation aerosols for targeted pulmonary nanomedicine. In Nanomedicine in Drug Delivery; Kumar, A., Mansour, H.M., Friedman, A., Blough, E.R., Eds.; CRC Press, Taylor & Francis Group: Boca Raton, FL, USA, 2013; pp. 43-74.
17. Maeda, H. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 2001, 41, 189-207.
18. Maeda, H.; Nakamura, H.; Fang, J. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug Deliv. Rev. 2013, 65, 71-79.
19. Chung, H.A.; Kato, K.; Itoh, C.; Ohhashi, S.; Nagamune, T. Casual cell surface remodeling using biocompatible lipid-poly(ethylene glycol)(n): Development of stealth cells and monitoring of cell membrane behavior in serum-supplemented conditions. J. Biomed. Mater. Res. Part A 2004, 70A, 179-185.
20. Yowell, S.L.; Blackwell, S. Novel effects with polyethylene glycol modified pharmaceuticals. Cancer Treat. Rev. 2002, 28, 3-6.
21. Bailon, P.; Berthold, W. Polyethylene glycol-conjugated pharmaceutical proteins. Pharm. Sci. Technol. Today 1998, 1, 352-356.
22. Liu, Q.; de Felippis, M.R.; Huang, L. Method for characterization of pegylated bioproducts in biological matrixes. Anal. Chem. 2013, 85, 9630-9637.
23. Zhang, X.; Gan, Y.; Gan, L.; Nie, S.; Pan, W. Pegylated nanostructured lipid carriers loaded with 10-hydroxycamptothecin: An efficient carrier with enhanced anti-tumour effects against lung cancer. J. Pharm. Pharmacol. 2008, 60, 1077-1087.
24. Zhang, F.; Liu, M.R.; Wan, H.T. Discussion about several potential drawbacks of pegylated therapeutic proteins. Biol. Pharm. Bull. 2014, 37, 335-339.
25. Swaminathan, J.; Gobbo, O.L.; Tewes, F.; Healy, A.M.; Ehrhardt, C. Encapsulation into PEG-liposomes does not improve the bioavailability of pulmonary delivered salmon calcitonin. J. Aerosol Med. Pulm. Drug Deliv. 2014, 27, 1-11.
26. Vartany, E.; Caldwell, C.A.; Trow, T.K. Adult respiratory distress syndrome after treatment with PEGylated interferon α-2a and ribavirin. Heart Lung 2008, 37, 153-156.
27. Inaba, K.; Arimoto, T.; Hoya, M.; Kawana, K.; Nakagawa, S.; Kozuma, S.; Taketani, Y. Interstitial pneumonitis induced by PEGylated liposomal doxorubicin in a patient with recurrent ovarian cancer. Med. Oncol. 2012, 29, 1255-1257.
28. Trullas, V.J.C.; Padilla, L.D.R.; Bisbe, C.V.; Soler, S.S.; Cortes, H.P.; Bisbe, C.J. Organizing pneumonia associated with the use of PEGylated interferon α. Arch. Bronconeumol. 2008, 44, 173-174.
29. Nevadunsky, N.S.; Mbagwu, C.; Mizrahi, N.; Burton, E.; Goldberg, G.L. Pulmonary fibrosis after PEGylated liposomal doxorubicin in a patient with uterine papillary serous carcinoma. J. Clin. Oncol. 2013, 31, e167-e169.
30. Mark, M.; Thurlimann, B. Fatal pneumonitis after treatment with pegylated liposomal doxorubicin in a patient with metastatic breast cancer in complete remission. Med. Oncol. 2012, 29, 1477-1478.
31. Kraft, J.C.; Freeling, J.P.; Wang, Z.; Ho, R.J. Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J. Pharm. Sci. 2014, 103, 29-52.
32. Willis, L.; Hayes, D., Jr.; Mansour, H.M. Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery. Lung 2012, 190, 251-262.
33. Awasthi, V.D.; Garcia, D.; Goins, B.A.; Phillips, W.T. Circulation and biodistribution profiles of long-circulating peg-liposomes of various sizes in rabbits. Int. J. Pharm. 2003, 253, 121-132.
34. Chono, S.; Suzuki, H.; Togami, K.; Morimoto, K. Efficient drug delivery to lung epithelial lining fluid by aerosolization of ciprofloxacin incorporated into PEGylated liposomes for treatment of respiratory infections. Drug Dev. Ind. Pharm. 2011, 37, 367-372.
35. Janoff, A.S. Liposomes Rational Design; Marcel Dekker Inc.: New York, NY, USA, 1999; p. 451.
36. Molineux, G. Pegylation: Engineering improved biopharmaceuticals for oncology. Pharmacotherapy 2003, 23, 3S-8S.
37. Mansour, H.M.; Rhee, Y.S.; Park, C.W.; DeLuca, P.P. Lipid Nanoparticulate Drug Delivery and Nanomedicine, 1st ed.; American Oil Chemists Society (AOCS) Press: Chicago, IL, USA, 2011; pp. 221-268.
38. Illum, L. Nanoparticulate systems for nasal delivery of drugs: A real improvement over simple systems? J. Pharm. Sci. 2007, 96, 473-483.
39. Zhang, C.; Chen, J.; Feng, C.; Shao, X.; Liu, Q.; Zhang, Q.; Pang, Z.; Jiang, X. Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer's disease. Int. J. Pharm. 2014, 461, 192-202.
40. Kim, T.H.; Park, C.W.; Kim, H.Y.; Chi, M.H.; Lee, S.K.; Song, Y.M.; Jiang, H.H.; Lim, S.M.; Youn, Y.S.; Lee, K.C. Low molecular weight (1 kDa) polyethylene glycol conjugation markedly enhances the hypoglycemic effects of intranasally administered exendin-4 in type 2 diabetic db/db mice. Biol. Pharm. Bull. 2012, 35, 1076-1083.
41. Youn, Y.S.; Jeon, J.E.; Chae, S.Y.; Lee, S.; Lee, K.C. PEGylation improves the hypoglycaemic efficacy of intranasally administered glucagon-like peptide-1 in type 2 diabetic db/db mice. Diabetes Obes. Metab. 2008, 10, 343-346.
42. Casettari, L.; Vllasaliu, D.; Castagnino, E.; Stolnik, S.; Howdle, S.; Illum, L. PEGylated chitosan derivatives: Synthesis, characterizations and pharmaceutical applications. Prog. Polym. Sci. 2012, 37, 659-685.
43. Lee, K.C.; Park, M.O.; Na, D.H.; Youn, Y.S.; Lee, S.D.; Yoo, S.D.; Lee, H.S.; DeLuca, P.P. Intranasal delivery of pegylated salmon calcitonins: Hypocalcemic effects in rats. Calc. Tissue Int. 2003, 73, 545-549.
44. Sharma, S.; Mukkur, T.K.S.; Benson, H.A.E.; Chen, Y. Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. J. Pharm. Sci. 2009, 98, 812-843.
45. Croyle, M.A.; Patel, A.; Tran, K.N.; Gray, M.; Zhang, Y.; Strong, J.E.; Feldmann, H.; Kobinger, G.P. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One 2008, 3, e3548.
46. Liu, Q.; Shen, Y.; Chen, J.; Gao, X.; Feng, C.; Wang, L.; Zhang, Q.; Jiang, X. Nose-to-brain transport pathways of wheat germ agglutinin conjugated PEG-PLA nanoparticles. Pharm. Res. 2012, 29, 546-558.
47. Chekhonin, V.P.; Gurina, O.I.; Ykhova, O.V.; Ryabinina, A.E.; Tsibulkina, E.A.; Zhirkov, Y.A. Polyethylene glycol-conjugated immunoliposomes specific for olfactory ensheathing glial cells. Bull. Exp. Biol. Med. 2008, 145, 449-451.
48. Gao, X.; Tao, W.; Lu, W.; Zhang, Q.; Zhang, Y.; Jiang, X.; Fu, S. Lectin-conjugated PEG-PLA nanoparticles: Preparation and brain delivery after intranasal administration. Biomaterials 2006, 27, 3482-3490.
49. Suarez, S.; Hickey, A.J. Drug properties affecting aerosol behavior. Respir. Care 2000, 45, 652-666.
50. Lai, S.K.; Wang, Y.Y.; Hanes, J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 2009, 61, 158-171.
51. Har-el, Y.; Fiegel, J.; Dawson, M.; Hanes, J. Chapter 16: Gene Delivery to the Lung. In Pharmaceutical Inhalation Aerosol Technology; Hickey, A.J., Ed.; Marcel Dekker Inc.: New York, NY, USA, 2004; Volume 134, pp. 498-505.
52. Hickey, A.J.; Thompson, D.C. Chapter 1: Physiology of the Airways. In Pharmaceutical Inhalation Aerosol Technology; Hickey, A.J., Ed.; Marcel Dekker Inc.: New York, NY, USA, 2004; Volume 134, pp. 1-30.
53. Tseng, C.L.; Wu, S.Y.; Wang, W.H.; Peng, C.L.; Lin, F.H.; Lin, C.C.; Young, T.H.; Shieh, M.J. Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer. Biomaterials 2008, 29, 3014-3022.
54. Vllasaliu, D.; Fowler, R.; Stolnik, S. PEGylated nanomedicines: Recent progress and remaining concerns. Expert Opin. Drug Deliv. 2014, 11, 139-154.
55. Ernsting, M.J.; Murakami, M.; Roy, A.; Li, S.D. Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J. Control. Release 2013, 172, 782-794.
56. Hadidi, N.; Kobarfard, F.; Nafissi-Varcheh, N.; Aboofazeli, R. PEGylated single-walled carbon nanotubes as nanocarriers for cyclosporin a delivery. AAPS PharmSciTech 2013, 14, 593-600.
57. Castro, E.; Kumar, A. Chapter 1: Nanoparticles in Drug Delivery Systems. In Nanomedicine in Drug Delivery; CRC Press, Taylor & Francis Group: Boca Raton, FL, USA, 2013; pp. 4-13.
58. Liu, Y.; Hu, Y.; Huang, L. Influence of polyethylene glycol density and surface lipid on pharmacokinetics and biodistribution of lipid-calcium-phosphate nanoparticles. Biomaterials 2014, 35, 3027-3034.
59. Kutscher, H.L.; Chao, P.; Deshmukh, M.; Sundara Rajan, S.; Singh, Y.; Hu, P.; Joseph, L.B.; Stein, S.; Laskin, D.L.; Sinko, P.J. Enhanced passive pulmonary targeting and retention of pegylated rigid microparticles in rats. Int. J. Pharm. 2010, 402, 64-71.
60. Cryan, S.A. Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS J. 2005, 7, E20-E41.
61. Niven, R. Modulated drug therapy with inhalation aerosols. In Pharmaceutical Inhalation Aerosol Technology, 2nd ed.; Marcel Dekker Inc.: New York, NY, USA, 2003; pp. 551-570.
62. Meenach, S.A.; Anderson, K.W.; Zach Hilt, J.; McGarry, R.C.; Mansour, H.M. Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer. Eur. J. Pharm. Sci. 2013, 49, 699-711.
63. Ibricevic, A.; Guntsen, S.P.; Zhang, K.; Shrestha, R.; Liu, Y.; Sun, J.Y.; Welch, M.J.; Wooley, K.L.; Brody, S.L. PEGylation of cationic, shell-crosslinked-knedel-like nanoparticles modulates inflammation and enhances cellular uptake in the lung. Nanomedicine 2013, 9, 912-922.
64. Sahib, M.N.; Abdulameer, S.A.; Darwis, Y.; Peh, K.K.; Tan, Y.T. Solubilization of beclomethasone dipropionate in sterically stabilized phospholipid nanomicelles (SSMS): Physicochemical and in vitro evaluations. Drug Des. Dev. Ther. 2012, 6, 29-42.
65. Bai, S.; Ahsan, F. Inhalable liposomes of low molecular weight heparin for the treatment of venous thromboembolism. J. Pharm. Sci. 2010, 99, 4554-4564.
66. Lu, Y.; Park, K. Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. Int. J. Pharm. 2013, 453, 198-214.
67. Craparo, E.F.; Teresi, G.; Bondi, M.L.; Licciardi, M.; Cavallaro, G. Phospholipid-polyaspartamide micelles for pulmonary delivery of corticosteroids. Int. J. Pharm. 2011, 406, 135-144.
68. Lim, S.B.; Rubinstein, I.; Sadikot, R.T.; Artwohl, J.E.; Onyuksel, H. A novel peptide nanomedicine against acute lung injury: Glp-1 in phospholipid micelles. Pharm. Res. 2011, 28, 662-672.
69. Gill, K.K.; Nazzal, S.; Kaddoumi, A. Paclitaxel loaded PEG(5000)-dspe micelles as pulmonary delivery platform: Formulation characterization, tissue distribution, plasma pharmacokinetics, and toxicological evaluation. Eur. J. Pharm. Biopharm. 2011, 79, 276-284.
70. Bai, S.; Ahsan, F. Synthesis and evaluation of PEGylated dendrimeric nanocarrier for pulmonary delivery of low molecular weight heparin. Pharm. Res. 2009, 26, 539-548.
71. Gaspar, M.M.; Radomska, A.; Gobbo, O.L.; Bakowsky, U.; Radomski, M.W.; Ehrhardt, C. Targeted delivery of transferrin-conjugated liposomes to an orthotopic model of lung cancer in nude rats. J. Aerosol Med. Pulm. Drug Deliv. 2012, 25, 310-318.
72. Kleemann, E.; Neu, M.; Jekel, N.; Fink, L.; Schmehl, T.; Gessler, T.; Seeger, W.; Kissel, T. Nano-carriers for DNA delivery to the lung based upon a tat-derived peptide covalently coupled to peg-pei. J. Control. Release 2005, 109, 299-316.
73. Sung, D.K.; Kong, W.H.; Park, K.; Kim, J.H.; Kim, M.Y.; Kim, H.; Hahn, S.K. Noncovalenly PEGylated CTGF siRNA/pdmaema complex for pulmonary treatment of bleomycin-induced lung fibrosis. Biomaterials 2013, 34, 1261-1269.
74. Bai, S.; Gupta, V.; Ahsan, F. Cationic liposomes as carriers for aerosolized formulations of an anionic drug: Safety and efficacy study. Eur. J. Pharm. Sci. 2009, 38, 165-171.
75. Lee, K.C.; Chae, S.Y.; Kim, T.H.; Lee, S.; Lee, E.S.; Youn, Y.S. Intrapulmonary potential of polyethylene glycol-modified glucagon-like peptide-1s as a type 2 anti-diabetic agent. Regul. Pept. 2009, 152, 101-107.
76. World Health Organization. Available online: http://who.int/mediacentre/factsheets/fs310/en/ (accessed on 3 March 2014).
77. Claus, S.; Weiler, C.; Schiewe, J.; Friess, W. How can we bring high drug doses to the lung? Eur. J. Pharm. Biopharm. 2014, 86, 1-6.
78. Rahimpour, Y.; Kouhsoltani, M.; Hamishehkar, H. Alternative carriers in dry powder inhaler formulations. Drug Discov. Today 2014, 19, 618-626.
79. Freire-Moran, L.; Aronsson, B.; Manz, C.; Gyssens, I.C.; So, A.D.; Monnet, D.L.; Cars, O.; Group, E.-E.W. Critical shortage of new antibiotics in development against multidrug-resistant bacteria-time to react is now. Drug Resist. Updates 2011, 14, 118-124.
80. Andrade, F.; Rafael, D.; Videira, M.; Ferreira, D.; Sosnik, A.; Sarmento, B. Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases. Adv. Drug Deliv. Rev. 2013, 65, 1816-1827.
81. Osman, R.; Kan, P.L.; Awad, G.; Mortada, N.; El-Shamy, A.E.; Alpar, O. Spray dried inhalable ciprofloxacin powder with improved aerosolisation and antimicrobial activity. Int. J. Pharm. 2013, 449, 44-58.
82. Mukhopadhyay, A.; Basu, N.; Ghatak, N.; Gujral, P.K. Anti-inflammatory and irritant activities of curcumin analogues in rats. Agents Act. 1982, 12, 508-515.
83. Reddy, A.C.; Lokesh, B.R. Effect of dietary turmeric (Curcuma longa) on iron-induced lipid peroxidation in the rat liver. Food Chem. Toxicol. 1994, 32, 279-283.
84. Egan, M.E.; Pearson, M.; Weiner, S.A.; Rajendran, V.; Rubin, D.; Glockner-Pagel, J.; Canny, S.; Du, K.; Lukacs, G.L.; Caplan, M.J. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 2004, 304, 600-602.
85. El-Sherbiny, I.M.; Smyth, H.D.C. Controlled release pulmonary administration of curcumin using swellable biocompatible microparticles. Mol. Pharm. 2012, 9, 269-280.
86. Meenach, S.A.; Vogt, F.G.; Anderson, K.W.; Hilt, J.Z.; McGarry, R.C.; Mansour, H.M. Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols. Int. J. Nanomed. 2013, 8, 275-293.
87. Insulin inhalation-Pfizer/Nektar therapeutics: Hmr 4006, inhaled peg-insulin-Nektar, PEGylated insulin-Nektar. Drugs R&D 2004, 5, 166-170.